Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Clazosentan Sodium

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nxera Pharma inks deal with Handok to distribute PIVLAZ in South Korea
    Nxera Pharma inks deal with Handok to distribute PIVLAZ in South Korea

    16 Apr 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24084/nxera-pharma-inks-deal-with-handok-to-distribute-pivlaz-in-south-korea.html

    BIOSPECTRUM ASIA
    16 Apr 2024
    Share Share
    Nxera Announces Exclusive Supply & Distribution Agreement with Handok for PIVLAZ
    Nxera Announces Exclusive Supply & Distribution Agreement with Handok for PIVLAZ

    14 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/14/2862478/0/en/Nxera-Pharma-Announces-Exclusive-Supply-and-Distribution-Agreement-with-Handok-for-PIVLAZ-in-South-Korea.html

    GLOBENEWSWIRE
    14 Apr 2024
    Share Share
    Sosei Group Announces Marketing Approval for PIVLAZ 150 mg in South Korea
    Sosei Group Announces Marketing Approval for PIVLAZ 150 mg in South Korea

    07 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/07/2792220/0/en/Sosei-Group-Announces-Marketing-Approval-for-PIVLAZ-clazosentan-sodium-150-mg-in-South-Korea.html

    GLOBENEWSWIRE
    07 Dec 2023
    Share Share
    Idorsia announces the results of REACT a Phase 3 study of clazosentan
    Idorsia announces the results of REACT a Phase 3 study of clazosentan

    07 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/06/2601762/0/de/Idorsia-announces-th[…]patients-following-aneurysmal-subarachnoid-hemorrhage.html

    GLOBENEWSWIRE
    07 Feb 2023
    Share Share
    Idorsia's PIVLAZ (clazosentan) now available for patients in Japan
    Idorsia's PIVLAZ (clazosentan) now available for patients in Japan

    20 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/20/2425136/0/de/PIVLAZ-clazosentan-Idorsia-s-first-commercial-product-now-available-for-patients-in-Japan.html

    GLOBENEWSWIRE
    20 Apr 2022
    Share Share
    The Journal of Neurosurgery reports impact of clazosentan
    The Journal of Neurosurgery reports impact of clazosentan

    04 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/04/2415246/0/de/The-Journal-of-Neurosurgery-reports-impact-of-clazosentan-on-cerebral-vasospasm-related-morbidity-and-all-cause-mortality-after-aneurysmal-subarachnoid-hemorrhage.html

    GLOBENEWSWIRE
    04 Apr 2022
    Share Share